Increased half life & ability to subcutaneously inject are not small benefits. Early days. They have to prove efficacy remains or potentially is improved, but this will clearly be of interest by many players. Additionally, it continues to demonstrate the value of their DEP technology. The mere fact that DEP is now linked with Rendesivir will have thousands of investors reviewing SPLs DEP portfolio in more detail. The DEP word is getting out! watch out for potential phase II trial updates on DEP in coming weeks / months.
GLTAH
SPL Price at posting:
$1.73 Sentiment: Buy Disclosure: Held
